Clinical Trial Update: The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1) [Phase 1]

View source ↗

Summary

This Phase 1 trial assesses the tolerability of Saracatinib in subjects with lymphangioleiomyomatosis, and the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphangioleiomyomatosis

Drugs mentioned

• Saracatinib (saracatinib)

Snippet

Sponsor: Tony Eissa | Conditions: Pulmonary Lymphangioleiomyomatosis | Phase 1 | Status: COMPLETED